Rheumatic diseases have been associated with pathways of altered immunological tolerance, which can be detected before clinical symptoms develop. It is imperative evidence is gathered that relates these altered biomarkers to the clinical characteristics of rheumatic disease, in order to improve early diagnosis and identify effective targets for treatment. Comorbidities that are also associated with these changes in molecular mechanisms contribute to impaired quality of life and increased mortality in patients. Therefore there is a need for studies that go deeper in the understanding of these issues and their consequences for patients' qualify of life.
This Research Topic aims to include the most recent evidence of potential biomarkers in rheumatic diseases and their comorbidities. We are interested in gathering original articles, review articles and brief reports dealing with state-of-the-art techniques, new insights into pathogenesis, potential biomarkers, and recent advances in the study and treatment of comorbidities. We will include a collection of studies that highlight the importance of new molecules that could have potential as biomarkers of disease activity.
Rheumatic diseases have been associated with pathways of altered immunological tolerance, which can be detected before clinical symptoms develop. It is imperative evidence is gathered that relates these altered biomarkers to the clinical characteristics of rheumatic disease, in order to improve early diagnosis and identify effective targets for treatment. Comorbidities that are also associated with these changes in molecular mechanisms contribute to impaired quality of life and increased mortality in patients. Therefore there is a need for studies that go deeper in the understanding of these issues and their consequences for patients' qualify of life.
This Research Topic aims to include the most recent evidence of potential biomarkers in rheumatic diseases and their comorbidities. We are interested in gathering original articles, review articles and brief reports dealing with state-of-the-art techniques, new insights into pathogenesis, potential biomarkers, and recent advances in the study and treatment of comorbidities. We will include a collection of studies that highlight the importance of new molecules that could have potential as biomarkers of disease activity.
